Dr Jonsson is the author of Possible Imprinting and Microchimerism in Chronic Lymphocytic Leukemia and Related Lymphoproliferative Disorders which was recently published in Translational Oncogenomics.

The Editor in Chief of Translational Oncogenomics recently issued a call for papers.

Please describe your experience with Libertas Academica

I found the publishing process very good, easy and fast, and I was updated all the time. The referee report was competent, inspirating and helpful. The quality of layout, print and presentation in general was very nice, clear and easy for the reader to overlook. I was very satisfied.

What is the primary focus of your research?

Chronic lymphocytic leukemia (CLL) and malignant lymphomas (ML), their pathophysiology and genetics. Diagnostic procedures and treatment modalities.

What are the most exciting developments arising from current research in your area?

• The recent demonstration of familial susceptibility genes of CLL and ML, the genetic and epigenetic accumulation of mutated genes related to CLL allelic loci.

• The increasing knowledge on synergistic combinations of chemotherapy and CD-specific immunotherapy.

Who are your main collaborators? Please describe your work with them

Richard Houlston and Daniel Catovsky and their team in London, UK, with whom I have a close collaboration on genomewide screening. Martin Yuille in Manchester, UK, and Jørgen H. Olsen at the Cancer Registry in Copenhagen, Denmark, with whom my team is closely associated in epidemiological work on CLL, supported by Jørgen Hilden, Department of Biostatistics, University of Copenhagen, Denmark.

Gunnar Juliusson and Karin Karlsson, Department of Hematology, University of Lund, Sweden, are close friends and colleagues to our present team here in Oslo (Geir Tjønnfjord,Hematology Department, University of Oslo, Bernt Ly and Tom Johannesen, Norwegian Cancer Registry, Oslo.)

How did you come to be working in your research area?

I became interested in hematology as a medical student in Professor Aage Videbæk's laboratory in Copenhagen, later as his research fellow. In my Copenhagen time, I was invited to join the London group due to my access to the Danish Cancer Registry and its invaluabe amount of data for cancer epidemiology. And that work continued after I got my chair in Oslo, now also in collaboration with the Norwegian Cancer Registry.

What do you think about the development of open access publishing? What motivated you to use it?

Brisk and rapid circulation of new data and deductive considerations, faster response from fellow scientists perhaps. I like it but I do not have so much experience yet.

What articles and/or books have you published recently?

• Schaadt BK, Hendel HW, Gimsing P, Jønsson V, Pedersen H, Waldemar G, Hesse B. 99mAprotinin scintigraphy in amyloidosis. J Nuclear Med 2003; 44: 177-83

• Hilden J, Jønsson V, Wiik A. Pregnancy as exposure: A Mendelian model of the „impregnator load” as a trigger of foetus - vs.- mother processes, autoimmunity and leukaemia. Contr Clin Trials 2003; 24, suppl 3, 93

• Egelund Christensen B, Jønsson V. Blodsygdomme. In Schroeder TV, Schulze S, Hilsted J, Aldershvile J (eds) Basisbog i Medicin og Kirurgi. 3. udgave. København, Munksgaard Publ. 2004, pp. 727-767

• Gniadecki R, Rossen K, Ralfkier E, Thomsen K, Lange Skovgaard G, Jønsson V. CD56+ lymphoma with skin involvment,: Clinicopathological features and classification. Arch Dermatol 2004; 104: 427-36

• Jønsson V, Egelund Christensen M. Maligne hæmatologiske sygdomme. Rørth M, Storm HH (eds). Kræftsygdomme, Onkologi, København, FADL´s Forlag, 2004, pp 392- 411

• Karlsson K, Strömberg M, Jønsson V, Gill D, Hammerstrøm J, Wallvik J, Mulligan S, Bradstock K, Liliemark J, Juliusson G. Cladribin (CdA) or fludarabin (F) or high-dose intermittent chlorambucil (Chl) as first-line treatment of symptomatic chronic lymphocytic leukemia ? First interim analysis of data from the International Randomized Phase III Trial. Poster Session 740 III. Blood 2004; 104: 3470

• Egelund Christensen B, Jønsson V. Blodsygdomme. In Schroeder TV, Schulze S, Hilsted J, Aldershvile J (eds) Basisbog i Medicin og Kirurgi. 3. udgave. København, Munksgaard Publ. 2004, pp. 727-767

• Gniadecki R, Rossen K, Ralfkier E, Thomsen K, Lange Skovgaard G, Jønsson V. CD56+ lymphoma with skin involvment,: Clinicopathological features and classification. Arch Dermatol 2004; 104: 427-36

• Jønsson V, Egelund Christensen M. Maligne hæmatologiske sygdomme. Rørth M, Storm HH (eds). Kræftsygdomme, Onkologi, København, FADL´s Forlag, 2004, pp 392-411

• Karlsson K, Strömberg M, Jønsson V, Gill D, Hammerstrøm J, Wallvik J, Mulligan S, Bradstock K, Liliemark J, Juliusson G. Cladribin (CdA) or fludarabin (F) or high-dose intermittent chlorambucil (Chl) as first-line treatment of symptomatic chronic lymphocytic leukemia ? First interim analysis of data from the International Randomized Phase III Trial. Poster Session 740 III. Blood 2004; 104: 3470

• Jønsson V, Houlston R, Catovsky, Yuille M, Olsen JH, Fajber M, Brandt B, Sellick G, Allinson R, Wiik A. CLL family ”pedigree 14” revisited: 1947 – 2004. Leukemia 2005; 19: 1025-28

• Tjønnfjord G, Jønsson V, Ly B, Hammerstrøm J, Ernst P. Handlingsprogram for kronisk lymfatisk leukemi 2005. Norsk selskab for hematologi, national rekommendasjon

• Karlsson K, Stromberg M, Willander K, Jonsson V, Hammerstrom J, Uggla B, Wallvik J, Sundstrom G, Geisler C, Tobin G, Rosenquist R, Liliemark J, Juliusson G. IgH mutation status is of limited prognostic value in untreated symptomatic CLL patients, results from the prospective Internation Phase III Study. Leukemia & Lymphoma 2005; 46, S38

• Sellick GS, Webb EL, Allinson R, Matutes E, Dyer MJS, Jønsson V, Langerak AW, Mauro FR, Fuller S, Wiley J, Lyttelton M, Callea V, Yuille M, Catovsky D, Houlston R. A high-density SNP genomewide linkage scan for chronic lymphocytic leukemia-susceptibility loci. Am J Hum Genet 2005; 77: 420-29

• Lotfi K, Karlsson K, Fyrberg A, Juliusson G, Jønsson V, Petersen C, Eriksson S, Albertioni F. The pattern of deoxycytidine- and deoxyguanosine kinase activity in relation to messenger RNA expression in blood cells from untreated patients with B-cell chronic lymphocytic leukemia. Biochem Pharmacol 2006; 71: 882-90

• Jønsson V, Bock JE, Hilden J, Houlston RS, Wiik A. The influence of pregnancy on the development of autoimmunity in chronic lymphocytic leukemia. Leukemia & Lymphoma 2006; 47: 1481-87

• Jønsson V, Johannesen TB. Anticipation in lymphoproliferative disorders (editorial). Leukemia & Lymphoma 2006; 47: 2015-16

• Jønsson V. Arv og kræft (editorial). Ugeskr f Læg (Copenhagen) 2006; 168: 2327

• Jønsson V, Olsen JH. Arv og lymfoproliferativ sygdom. Ugeskr f Læg (Copenhagen) 2006: 168: 2361-66

• Bergmann O, Bruun B, Egelund Christensen B, Frimodt-Møller N, Jønsson V, Peterslund NA, Skinhøj P, Tvede M. Infektioner hos hæmatologiske og onkologiske patienter. Odense, Odense Universitetsforlag, 2006, ISBN 87-7674-075-7, pp 1-126

• Jønsson V, Christensen BE. Jern, B-vitaminer og medikamentell knoglemarvspåvirkning. In Kampmann JP, Brøsen K, Simonsen U (eds) Basal og Klinisk Farmakologi, 3. udgave, København, FADL´s Forlag, 2007, Kapitel 58, pp 655-64

• Jønsson V, Hasselbalch, Christensen BE. Blodsygdomme. In Schroeder TV, Schulze S, Hilsted J, Gøtzsche L (eds) Basisbog i Medicin og Kirurgi, 4. udgave. København, Munksgaard Publ., Gyldendal, 2007, Kapitel 21, pp 693-736

• Jønsson V, Tjønnfjord GE, Samuelsen SO, Johannesen TB, Ly B. Pleiotrophy in familial CLL. Leukemia & Lymphoma 2007; 48: S124

• Karlsson K, Strömberg M, Jønsson V, Mulligan S, Liliemark J, Juliusson G. Improved response duration from first-line treatment with cladribine (CdA) as compared to fludarabine (F) or high-dose intermittent chlorambucil (Chl) for first-line treatment of symptomatic chronic lymphocytic leukemia (CLL). First results from the International Randomized Phase III Trial. Leukemia & Lymphoma 2007; 48: S167-68

• Jønsson V, Johannesen TB, Samuelsen SO, Ly B, Bock J, Tjønnfjord GE. On the genetics of chronic lymphocytic leukemia. Annotation. Elsevier Inform, Buenos Aires, submitted on Editor´s request 2007, www.siicsalud.com. November 6th,2007

• Jønsson V, Tjønnfjord G, Samuelsen SO, Johannesen T, Olsen J, Sellick G, Houlston R, Yuille M, Catovsky D. Birth order pattern in the inheritance of chronic lymphocytic leukaemia and related lymphoproliferative diseases. Leukemia & Lymphoma 2007; 48: 2387-96

• Karlsson K, Strömberg M, Jønsson V, Mulligan S, Liliemark J, Juliusson G. Improved response duration from first-line treatment with cladribine (CdA) as compared to fludarabine (F) or high-dose intermittent chlorambucil (Chl) for first-line treatment of symptomatic chronic lymphocytic leukemia (CLL). First results from the International Randomized Phase III Trial. Leukemia & Lymphoma 2007; 48: S167-68

• Jønsson V, Tjønnfjord G, Samuelsen SO, Johannesen T, Olsen J, Sellick G, Houlston R, Yuille M, Catovsky D. Birth order pattern in the inheritance of chronic lymphocytic leukaemia and related lymphoproliferative diseases published in Leukemia and Lymphoma. www.Slidesonline.org , by invitation, (Medical Online Digital Library, US), 2008

• Jønsson V, Samuelsen SO, Tjønnfjord GE, Johannesen TB. Looking for CLL genes. Leukemia & Lymphoma 2008; 49: 10-11

• Johannesen TB, Ly B, Samuelsen SO, Tjønnfjord GE, Jønsson V. Nye studier om kronisk lymfatisk leukemia i Norge. Tidsskr Nor Lægeforening 2008; 128: 713

• Olsen AL, Johannesen TB, Ly B, Samuelsen SO, Tjønnfjord G, Jønsson V. Pleiotropy in families with chronic lymphocytic leukemia, and Pleiotropia en familias con leukemia linfocittica cronica. Salud(i)Ciencia (Buenos Aires) 2008;15:1236-41

• Jønsson V, Tjønnfjord GE, Johannesen TB, Samuelsen SO, Ly B. Possible imprinting and microchimerism in chronic lymphocytic leukemia and related lymphoproliferative disorders. Translational Oncogenomics 2008, 3: 1-6

• Kolstad A, Tjønnfjord G, Jønsson V. High frequency of unrecognized indolent hematological disorders among HLA-matched siblings of patients with lymphoproliferative malignancies eligible for allogeneic stem cell transplantation. Bone Marrow Transplant, 2008; 42:427-8

• Crowther D, Wild R, Sellick G, Dyer MJS, Mauro FR, Cuthbert JG, Jønsson V, Matutes E, Dearden C, Wiley J, Fuller S, Catovsky D, Houlston RS. Insight into the pathogenesis of chronic lymphocytic leukemia (CLL) through analysis of IgVH gene usage and mutation status in familial CLL. Blood 2008; 111: 5691-93

• Jønsson V, Johannesen TB, Samuelsen SO, Ly B, Bock J, Tjønnfjord GE. Aspectos geneticos de la leukemia linfocitica cronica. Salud Cienia (Buenos Aires) 2008; 16:1318

• Jønsson V. Birth order effect in the inheritance of chronic lymphocytic leukemia. Anticancer Res 2008; 5C, 3337 a

• Jønsson V, Awan H, Johannenesen T, Tjønnfjord G. Birth order effect in the inheritance of CLL. Haematologica 2009; supp. 3, s2

• Jønsson V, Christensen BE. Jern, B-vitaminer og medikamentell knoglemarvspåvirkning. In Kampmann JP, Brøsen K, Simonsen U (eds) Basal og Klinisk Farmakologi, 4. udgave, København, FADL´s Forlag, 2009, in press.

Other information

share on